Jazz Pharmaceuticals (JAZZ) Projected to Post Quarterly Earnings on Monday

Jazz Pharmaceuticals (NASDAQ:JAZZ) is projected to release its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to post earnings of $6.18 per share and revenue of $1.1144 billion for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The firm had revenue of $1.07 billion for the quarter. On average, analysts expect Jazz Pharmaceuticals to post $22 EPS for the current fiscal year and $22 EPS for the next fiscal year.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $253.87 on Monday. Jazz Pharmaceuticals has a 12 month low of $105.00 and a 12 month high of $256.75. The company has a market capitalization of $15.95 billion, a P/E ratio of -12,687.16, a PEG ratio of 0.22 and a beta of 0.32. The company’s 50 day simple moving average is $237.37 and its 200 day simple moving average is $203.44. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director owned 18,449 shares in the company, valued at $4,446,209. This represents a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark Douglas Smith sold 1,157 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the completion of the sale, the director directly owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. This trade represents a 10.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 13,098 shares of company stock worth $3,131,906. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently bought and sold shares of JAZZ. Royal Bank of Canada grew its stake in Jazz Pharmaceuticals by 96.5% during the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after acquiring an additional 33,210 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 147.7% during the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after purchasing an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Jazz Pharmaceuticals by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after purchasing an additional 7,954 shares in the last quarter. Focus Partners Wealth increased its stake in Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after buying an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. increased its stake in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JAZZ. Wells Fargo & Company raised their price objective on Jazz Pharmaceuticals from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Leerink Partners upped their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Morgan Stanley reiterated an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $239.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $259.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.